In a report released yesterday, Deane Dray from RBC Capital maintained a Sell rating on 3M (MMM – Research Report), with a price target of ...

J.P. Morgan analyst Anthony Paolone maintained a Buy rating on W. P. Carey Inc. (WPC – Research Report) on January 16 and set a price target of ...

The move is the latest recruiting win for RBC Wealth Management as it continues to lure top talent away from big banks and ...

capital markets at Datos Insights. "Through decades of work, FactSet and J.P. Morgan have created a viable product that adds FactSet analytics and ESG benchmarking data to performance and risk data." ...

While Biogen has made an opportunistic bid for partner Sage, its top executive seemed to play down the urgency for his ...

J.P. Morgan analysts said the CMS’ review “validates the technology and could potentially move the needle on growth for Medtronic.” ...

Kimbell Royalty Partners, LP (NYSE: KRP) disclosed today that on January 7, 2025, the company entered into an Underwriting Agreement. The agreement includes Kimbell Royalty GP, LLC, Kimbell Royalty ...

Issuance was led by a $2 billion retail pricing from the University of California in the negotiated market and a $1.2 billion competitive deal from Washington.

On Thursday, RBC Capital Markets adjusted its outlook on shares ... With a market capitalization of $709.92 billion and a P/E ratio of 12.93, JPM has maintained dividend payments for 55 ...

"These opportunities will surface periodically throughout the year against heavy supply and the increasingly uncertain path for the Fed, evolving fiscal policy, and volatile Treasury market backdrop," ...

Intra-Cellular has had success selling Caplyta, a brain-rebalancing drug that's approved to treat schizophrenia and bipolar ...